Comparison of a 755-nm picosecond laser and a 1565-nm nonablative fractional laser for the treatment of atrophic acne scars: a 20-week prospective, randomized, split-face clinical study Authors: Junfeng Qi, Xinying Li, Xia Shu, Bingni Zhou, Zhouna Li Published: 2026 ABSTRACT To compare the efficacy and safety of a 755-nm picosecond laser with a diffractive lens array (P-DLA) and a 1565-nm nonablative fractional laser (NAFL) for the treatment of atrophic acne scars. Twenty-seven patients with atrophic acne scars underwent three sessions of randomized split-face treatment with P-DLA and NAFL at 4-week intervals. Patients were followed up at 1, 2, and 3 months after the final treatment. Efficacy was assessed using the Échelle d’Évaluation Clinique des Cicatrices d’Acné (ECCA) grading scale, the Investigator’s Global Assessment (IGA) score, patients’ self-rated improvement, and overall satisfaction. Treatment-related adverse reactions were recorded daily by patients until resolution. Both modalities demonstrated significant improvements in scar appearance based on ECCA score, IGA score, and patients’ self-rated improvement (P < 0.001). No statistically significant differences in efficacy were observed between the two treatments. However, the P-DLA group showed higher patient satisfaction (P = 0.035) and a more favorable safety profile, including shorter durations of erythema and edema and the absence of crusting. Both P-DLA and NAFL were effective and safe for the treatment of atrophic acne scars, with similar efficacy. P-DLA offered better tolerability. Introduction Atrophic acne scars are a common sequela of acne vulgaris and impose substantial long-term aesthetic and psychosocial burdens [1, 2]. Currently, a wide range of treatment options are available for atrophic acne scars, including various lasers, radiofrequency devices, dermabrasion, soft tissue fillers, and surgical methods. Laser-based approaches play an increasingly important role in scar management, with emerging multimodal strategies combining different laser modalities to target specific scar components [3]. Recent advances in laser technologies have expanded their applications to active acne management [4]. Among the various laser modalities, fractional laser technology has become one of the most widely used treatment modalities for atrophic acne scars [5–7]. However, traditional ablative fractional lasers are often accompanied by significant pain, a longer recovery period, and a greater risk of postinflammatory hyperpigmentation (PIH), especially in patients with darker skin tones [8, 9]. Therefore, nonablative fractional lasers (NAFLs) with milder adverse reactions are also widely used in the treatment of atrophic acne scars. NAFL creates microthermal treatment zones (MTZs) in the dermis through selective water absorption, thereby inducing a wound-healing response and promoting collagen remodeling. Previous studies have demonstrated its efficacy in the treatment of atrophic acne scars. However, treatment-related adverse effects and prolonged downtime may still occur [10–12]. Therefore, developing effective treatment modalities with improved tolerability and reduced downtime remains an important clinical challenge. Picosecond lasers represent a novel laser technology characterized by ultrashort picosecond pulse duration, enabling a shift in the mechanism of action from conventional photothermal to photomechanical effects. The 755-nm picosecond alexandrite laser was initially developed for the treatment of tattoos and pigmented lesions. A specialized handpiece with a diffractive lens array (DLA) was subsequently introduced to generate a fractional array of focused, high-fluence microspots surrounded by a low-fluence background. Upon selective absorption of fractional laser energy by melanin, laser-induced optical breakdown (LIOB) occurs in the epidermis. The resultant photomechanical stress waves propagate into the dermis, inducing fibroblast proliferation, neocollagenesis, and cutaneous remodeling [13–15]. There is growing evidence that the 755-nm picosecond laser with DLA (P-DLA) has substantial potential for treating atrophic acne scars and is associated with milder adverse effects owing to its minimal thermal damage [16–18]. Nevertheless, to date, there have been insufficient prospective comparative studies evaluating P-DLA versus current NAFLs for the treatment of atrophic acne scars. Here, we report a prospective, randomized, split-face, evaluator-blinded study comparing the efficacy and safety of a 755-nm P-DLA and a 1565-nm NAFL for the treatment of atrophic acne scars. Materials and methods Study design This was a prospective, randomized, split-face, evaluator-blinded study comparing the efficacy and safety of P-DLA and NAFL for the treatment of atrophic acne scars. Study population Patients with atrophic acne scars were enrolled from April to July 2025. Owing to the lack of prior comparative data, this study was designed as an exploratory pilot study to provide preliminary comparative data on efficacy and safety between the two laser systems. Therefore, the sample size was determined on the basis of feasibility considerations, including patient availability, study duration, and the exploratory nature of this pilot study, rather than a formal power calculation. The inclusion criteria for this study were as follows: the presence of similar atrophic acne scars on both sides of the face and Fitzpatrick skin types III–IV. The exclusion criteria included a history of keloid formation, allergy to lidocaine, photosensitivity or use of photosensitizing drugs within the past 6 months, bleeding disorders or use of anticoagulant drugs, severe systemic disease or use of immunosuppressive drugs, infectious skin diseases, pregnancy, and prior phototherapy within the past 6 months. Randomization Randomization of the treatment side was performed using a lottery method. Two identical, opaque, sealed envelopes were prepared, each containing a card indicating one of the two possible treatment-side assignments. Each patient randomly selected one envelope immediately prior to treatment to determine the allocation of P-DLA and NAFL to the left and right sides of the face. Treatment protocol Enrolled patients were randomized to receive split-face treatment with a 755-nm P-DLA (PicoSure™; Cynosure Inc., Westford, MA, USA) on one facial side and a 1565-nm NAFL (M22-ResurFX™; Lumenis, Salt Lake City, UT, USA) on the contralateral side. The laser parameters for both devices were selected on the basis of previously published studies and clinical practice. A topical anesthetic cream containing lidocaine 2.5% and prilocaine 2.5% (Tongfang Pharmaceutical Co., Ltd., Beijing, China) was applied on both sides of the face under occlusion for 40 min prior to the laser treatment. The parameters for the P-DLA side were as follows: P-DLA was applied for five passes using a 6-mm spot size, a fluence of 0.71 J/cm², a repetition rate of 10 Hz, and a pulse width of 750 picoseconds. Laser pulses were preferentially delivered to the atrophic acne scar areas. On the NAFL side, two passes were performed per session: the initial pass targeted atrophic acne scars with a 5-mm circular spot size, a density of 150–250 spots/cm2 and an energy of 60 mJ/cm2; the second pass uniformly covered the entire lesion area using a 12-mm square spot size, a density of 200–250 spots/cm2, and an energy of 40–45 mJ/cm2. The laser parameters for both treatment modalities are presented in Table 1. Treatment was confined to the atrophic acne scars without intentional feathering or extension beyond the target areas. Proper eye protection was used throughout all the procedures. After treatment, a medical-grade mask and ice packs were applied for 20 min. Patients were instructed to avoid sun exposure for at least 2 weeks. All patients received three consecutive laser sessions at 4-week intervals, with follow-up visits scheduled at 1, 2, and 3 months after the final treatment. Table 1Laser parameters for P-DLA and NAFL treatmentsParameterP-DLANAFLSpot size6 mm5 mm / 12 mmPasses52Energy0.71 J/cm²40–60 mJ/cm²Density/150–250 spots/cm²Repetition rate10 Hz/Pulse width750 ps/ Table 1Laser parameters for P-DLA and NAFL treatmentsParameterP-DLANAFLSpot size6 mm5 mm / 12 mmPasses52Energy0.71 J/cm²40–60 mJ/cm²Density/150–250 spots/cm²Repetition rate10 Hz/Pulse width750 ps/ Laser parameters for P-DLA and NAFL treatments Data collection and outcome measurements Data regarding age, sex, and Fitzpatrick skin type were recorded in the case record form. Standardized facial photographs were obtained from the frontal, left, and right views using digital imaging software (VISIA CR; Canfield Scientific, Fairfield, NJ, USA) prior to each treatment session and at 1, 2, and 3 months after the final treatment. The efficacy of the scar treatments was assessed using anonymized clinical photographs by two independent dermatologists who were blinded to both treatment allocation and follow-up time points. Evaluations were performed using the Échelle d’Évaluation Clinique des Cicatrices d’Acné (ECCA) grading scale and the Investigator’s Global Assessment (IGA) score. The ECCA score was calculated on the basis of the sum of the number and type of scars (icepick, boxcar, and rolling scars) [19]. The IGA score was determined using a 5-point scale associated with the degree of improvement (grade 0 = no improvement; 1 = 1–25% improvement; 2 = 26%–50% improvement; 3 = 51–75% improvement; and 4 = 76–100% improvement). Patients were also required to assess the degree of scar improvement using a 5-point scale (grade 0 = no improvement; 1 = 1–25%; 2 = 26–50%; 3 = 51–75%; and 4 = 76–100% improvement) at each visit. At the final follow-up, patients’ overall satisfaction, considering both therapeutic efficacy and adverse reactions, was assessed using a 5-point scale (-2 = very dissatisfied; -1 = dissatisfied; 0 = no opinion; 1 = satisfied; and 2 = very satisfied). The primary outcome was the change in the ECCA score from baseline to 3 months after the final treatment session. The secondary outcomes included changes in the ECCA and IGA scores and patients’ self-rated improvement scores at each follow-up visit, as well as patients’ overall satisfaction at the final follow-up visit. Regarding safety outcomes, patients were asked to rate their pain immediately after each treatment session using a visual analog scale (VAS) ranging from 0 (no pain) to 10 (unbearable pain). Other immediate adverse reactions, including erythema, edema, and burning sensation, were recorded using a 0–3 severity scale (0 = none; 1 = mild; 2 = moderate; 3 = severe). To monitor potential long-term adverse reactions, patients were also instructed to document their daily skin condition following treatment, including the presence of erythema, edema, crusting, pruritus, blistering, and postinflammatory hyperpigmentation (PIH), until resolution. Statistical analysis All statistical analyses were conducted on a per-protocol basis. Only patients who completed the study protocol and all follow-up evaluations were included in the final analysis. The data were analyzed using SPSS software (version 29.0). A P value < 0.05 was considered to indicate statistical significance. Descriptive data are presented as mean ± standard deviation (SD). Normality was assessed using the Shapiro–Wilk test. Changes in ECCA, IGA, and patients’ self-rated improvement scores over time within each treatment side were assessed using the Friedman test. Comparisons between the P-DLA and NAFL treatment sides were performed using paired t tests or Wilcoxon signed-rank tests for normally and non-normally distributed variables, respectively. Categorical variables were analyzed using the McNemar test. Results Patient characteristics Of the 38 patients screened, 31 were included in the study. Seven were excluded because they did not meet the eligibility criteria. Among the included patients, four did not complete the study: three discontinued treatment because of scheduling conflicts, and one missed two follow-up visits owing to job-related constraints. Therefore, these four patients were not included in the final analysis due to incomplete follow-up data. The remaining 27 patients who completed the study were analyzed using a per-protocol approach. No intention-to-treat analysis was conducted. Baseline patient demographic characteristics are shown in Table 2. There was no significant difference in the mean ECCA score at baseline between one side of the face and the other. Table 2Demographic characteristics of the patientsNo. of patients who completed the study27Age (year), mean ± SD29.96 ± 4.14Sex, n (%)Female13 (48.15%)Male14 (51.85%)Fitzpatrick skin type, n (%)Type Ⅲ5 (18.52%)Type Ⅳ22 (81.48%) Table 2Demographic characteristics of the patientsNo. of patients who completed the study27Age (year), mean ± SD29.96 ± 4.14Sex, n (%)Female13 (48.15%)Male14 (51.85%)Fitzpatrick skin type, n (%)Type Ⅲ5 (18.52%)Type Ⅳ22 (81.48%) Demographic characteristics of the patients Physician assessment of scar treatment efficacy Changes in ECCA scores from baseline to the final follow-up are presented in Fig. 1. Both lasers significantly improved the appearance of atrophic acne scars after three treatment sessions; however, no statistically significant differences in ECCA scores were observed between the two laser groups at any follow-up visit. In the P-DLA group, the mean ECCA score decreased from 119.63 ± 25.00 at baseline to 91.67 ± 23.82 at the final follow-up, corresponding to a mean reduction of 27.96 points (23.37% improvement; P < 0.001). In the NAFL group, the mean ECCA score decreased from 119.07 ± 24.50 to 93.24 ± 25.00, with a mean reduction of 25.83 points (21.69% improvement; P < 0.001). In addition, a significant reduction in ECCA scores compared with baseline was observed after the two treatment sessions in both groups. The IGA scores tended to be similar to the ECCA scores (Fig. 2). At the final follow-up visit, 55.56% (15/27) of the facial sides that received P-DLA, and 70.37% (19/27) of those that received NAFL achieved an IGA score of ≥ 2 (P = 0.125). Representative cases are shown in Fig. 3. Fig. 1Mean ECCA scores evaluated from baseline to the final follow-up. The error bars represent the SDs. ECCA, Échelle d’Évaluation Clinique des Cicatrices d’Acné (Scale for Clinical Evaluation of Acne Scars); P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser. *P < 0.05 compared with baseline; **P < 0.01 compared with baseline; ***P < 0.001 compared with baseline Mean ECCA scores evaluated from baseline to the final follow-up. The error bars represent the SDs. ECCA, Échelle d’Évaluation Clinique des Cicatrices d’Acné (Scale for Clinical Evaluation of Acne Scars); P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser. *P < 0.05 compared with baseline; **P < 0.01 compared with baseline; ***P < 0.001 compared with baseline Fig. 2Evaluation of scar appearance after treatment on the basis of the IGA score. (a) The mean IGA scores of each side were evaluated from the first treatment to the final follow-up. (b) Evaluation of scar appearance at the final follow-up. IGA, Investigator’s Global Assessment; P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser. ***P < 0.001 compared with the first treatment Evaluation of scar appearance after treatment on the basis of the IGA score. (a) The mean IGA scores of each side were evaluated from the first treatment to the final follow-up. (b) Evaluation of scar appearance at the final follow-up. IGA, Investigator’s Global Assessment; P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser. ***P < 0.001 compared with the first treatment Fig. 3Clinical photographs revealed improvement in the appearance of atrophic acne scars with both therapeutic modalities. (A) A 31-year-old woman. (B) A 27-year-old man. (a–d) P-DLA-treated side of the face; (e–h) NAFL-treated side of the face. (a, c, e, g) Before treatment; (b, d, f, h) Three months after three treatment sessions. P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser Clinical photographs revealed improvement in the appearance of atrophic acne scars with both therapeutic modalities. (A) A 31-year-old woman. (B) A 27-year-old man. (a–d) P-DLA-treated side of the face; (e–h) NAFL-treated side of the face. (a, c, e, g) Before treatment; (b, d, f, h) Three months after three treatment sessions. P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser Subgroup analyses based on scar subtypes Exploratory subgroup analyses of scar subtypes were performed to assess potential differences in ECCA score changes. Both P-DLA and NAFL significantly improved the appearance of icepick, boxcar, and rolling scars, with no significant differences observed between devices across scar subtypes (Table 3). Table 3ECCA scores after consecutive treatments for three major subtypes of scars on the ECCA grading scale (V, U, and M)LaserBaselineWeek 12Week 16Week 20V typeP-DLA36.67 ± 8.1531.67 ± 7.8828.89 ± 8.75***28.33 ± 8.41***NAFL35.83 ± 7.6030.83 ± 8.66**29.72 ± 8.44***28.33 ± 7.88***U typeP-DLA42.22 ± 10.8636.30 ± 11.4934.81 ± 10.87**33.70 ± 11.49***NAFL42.96 ± 11.0335.93 ± 13.3834.44 ± 14.76**32.96 ± 14.36**M typeP-DLA40.74 ± 13.6934.26 ± 14.5432.41 ± 12.62**29.63 ± 13.04***NAFL40.28 ± 15.2435.65 ± 13.2934.26 ± 12.7831.94 ± 13.13**The data are presented as the mean ± SD. V, U, and M indicate the types of atrophic acne scars (icepick, boxcar, and rolling)ECCA Échelle d’Évaluation Clinique des Cicatrices d’Acné (Scale for Clinical Evaluation of atrophic acne scars), P-DLA picosecond laser with a diffractive lens array, NAFL nonablative fractional laser*P < 0.05 between baseline and each time point; **P < 0.01 between baseline and each time point; ***P < 0.001 between baseline and each time point Table 3ECCA scores after consecutive treatments for three major subtypes of scars on the ECCA grading scale (V, U, and M)LaserBaselineWeek 12Week 16Week 20V typeP-DLA36.67 ± 8.1531.67 ± 7.8828.89 ± 8.75***28.33 ± 8.41***NAFL35.83 ± 7.6030.83 ± 8.66**29.72 ± 8.44***28.33 ± 7.88***U typeP-DLA42.22 ± 10.8636.30 ± 11.4934.81 ± 10.87**33.70 ± 11.49***NAFL42.96 ± 11.0335.93 ± 13.3834.44 ± 14.76**32.96 ± 14.36**M typeP-DLA40.74 ± 13.6934.26 ± 14.5432.41 ± 12.62**29.63 ± 13.04***NAFL40.28 ± 15.2435.65 ± 13.2934.26 ± 12.7831.94 ± 13.13**The data are presented as the mean ± SD. V, U, and M indicate the types of atrophic acne scars (icepick, boxcar, and rolling)ECCA Échelle d’Évaluation Clinique des Cicatrices d’Acné (Scale for Clinical Evaluation of atrophic acne scars), P-DLA picosecond laser with a diffractive lens array, NAFL nonablative fractional laser*P < 0.05 between baseline and each time point; **P < 0.01 between baseline and each time point; ***P < 0.001 between baseline and each time point ECCA scores after consecutive treatments for three major subtypes of scars on the ECCA grading scale (V, U, and M) The data are presented as the mean ± SD. V, U, and M indicate the types of atrophic acne scars (icepick, boxcar, and rolling) ECCA Échelle d’Évaluation Clinique des Cicatrices d’Acné (Scale for Clinical Evaluation of atrophic acne scars), P-DLA picosecond laser with a diffractive lens array, NAFL nonablative fractional laser *P < 0.05 between baseline and each time point; **P < 0.01 between baseline and each time point; ***P < 0.001 between baseline and each time point Patients’ subjective assessment The efficacy assessed by patients is shown in Fig. 4. Patients’ overall satisfaction was higher after P-DLA treatment than after NAFL treatment (1.44 ± 0.58 vs. 1.15 ± 0.60; P = 0.035). Specifically, in the P-DLA group, 13 of 27 patients (48.15%) reported “very satisfied”, and 13 of 27 (48.15%) reported “satisfied”, whereas in the NAFL group, 7 (25.93%) and 17 (62.96%) patients reported “very satisfied” and “satisfied”, respectively. Patients’ self-rated improvement was not significantly different between the two sides (P-DLA: 2.15 ± 0.72; NAFL: 2.04 ± 0.71; P = 0.453). Fig. 4Patients’ self-rated improvement and overall satisfaction. (a) Patients’ assessment of scar improvement after treatment. (b) Patients’ overall satisfaction. P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser Patients’ self-rated improvement and overall satisfaction. (a) Patients’ assessment of scar improvement after treatment. (b) Patients’ overall satisfaction. P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser Assessment of safety No significant differences in pain scores (3.21 ± 1.43 vs. 3.57 ± 1.58, P = 0.190) or burning sensation scores (1.06 ± 0.58 vs. 0.88 ± 0.48, P = 0.103) were detected between the P-DLA and NAFL groups (Table 4). Mild erythema and edema were observed in all patients immediately after both treatments. With respect to long-term adverse effects, the durations of erythema and edema were significantly shorter with P-DLA than with NAFL (duration of erythema: 2.11 ± 1.12 vs. 3.21 ± 2.41, P < 0.001; duration of edema: 1.21 ± 0.71 vs. 1.51 ± 1.08, P = 0.031) (Fig. 5). Crusting was not observed in the P-DLA group but occurred in 19 patients (70.37%) in the NAFL group (mean onset: 2.64 ± 0.86 days; mean duration: 2.60 ± 1.25 days). Pruritus incidence and duration were comparable between groups. Localized blistering occurred in 3 patients (11.11%) following P-DLA treatment and resolved within 1 week. No PIH or other permanent adverse events were observed. Table 4Description of postprocedural complications on both sidesAdverse eventP-DLA sideNAFL sideP valuePain score3.21 ± 1.433.57 ± 1.58P = 0.190Burning sensation score1.06 ± 0.580.88 ± 0.48P = 0.103Erythema (days)2.11 ± 1.123.21 ± 2.41P < 0.001Edema (days)1.21 ± 0.711.51 ± 1.08P = 0.031Crusting0/27 (0%)19/27 (70.37%)P < 0.001Pruritus10/27 (37.04%)11/27 (40.74%)P = 1.000Blisters3/27 (11.11%)0/27 (0%)P = 0.250Hyperpigmentation0/27 (0%)0/27 (0%)NAData are presented as the mean ± SD or proportion. NA not available, P-DLA picosecond laser with a diffractive lens array, NAFL nonablative fractional laser Table 4Description of postprocedural complications on both sidesAdverse eventP-DLA sideNAFL sideP valuePain score3.21 ± 1.433.57 ± 1.58P = 0.190Burning sensation score1.06 ± 0.580.88 ± 0.48P = 0.103Erythema (days)2.11 ± 1.123.21 ± 2.41P < 0.001Edema (days)1.21 ± 0.711.51 ± 1.08P = 0.031Crusting0/27 (0%)19/27 (70.37%)P < 0.001Pruritus10/27 (37.04%)11/27 (40.74%)P = 1.000Blisters3/27 (11.11%)0/27 (0%)P = 0.250Hyperpigmentation0/27 (0%)0/27 (0%)NAData are presented as the mean ± SD or proportion. NA not available, P-DLA picosecond laser with a diffractive lens array, NAFL nonablative fractional laser Description of postprocedural complications on both sides Data are presented as the mean ± SD or proportion. NA not available, P-DLA picosecond laser with a diffractive lens array, NAFL nonablative fractional laser Fig. 5Posttreatment skin reactions in a 31-year-old woman. Mild erythema and edema were observed after both laser treatments. Images were obtained before treatment (a, e) and at 1, 2, and 5 days post-treatment (b–d, f–h) for the 755-nm P-DLA (left) and the 1565-nm NAFL (right). P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser Posttreatment skin reactions in a 31-year-old woman. Mild erythema and edema were observed after both laser treatments. Images were obtained before treatment (a, e) and at 1, 2, and 5 days post-treatment (b–d, f–h) for the 755-nm P-DLA (left) and the 1565-nm NAFL (right). P-DLA, picosecond laser with a diffractive lens array; NAFL, nonablative fractional laser Discussion In this prospective, randomized, split-face, evaluator-blinded comparative study, both P-DLA and NAFL were effective in improving atrophic acne scars. Although a slightly greater improvement in ECCA score was observed on the P-DLA side compared with the NAFL side, this difference did not reach statistical significance, and its clinical relevance remains uncertain. The greater patient satisfaction and more favorable safety profile reported in the P-DLA group may reflect a better recovery experience. Continued improvement was observed during the posttreatment follow-up period, indicating that further scar improvement may occur after treatment completion. An analysis of the potential mechanisms underlying these two treatment modalities may help interpret the observed clinical outcomes. On the basis of previous histological and mechanistic studies, differences in wavelength and mechanism of action are thought to contribute to distinct tissue responses between the two laser systems. NAFL primarily targets water through fractional photothermolysis, creating MTZs in the dermis that may trigger subsequent collagen remodeling [10]. Although NAFL is considered non-ablative at the epidermal surface, prior studies have suggested that unwanted thermal exposure may still induce focal epidermal necrosis within MTZs, potentially contributing to transient crusting [20]. In contrast, P-DLA is thought to interact primarily with epidermal melanin and may induce LIOB within the epidermis. The resulting pressure waves may propagate into the dermis and potentially influence cellular signaling and promote dermal remodeling [21]. Histological studies of picosecond lasers have reported that the stratum corneum and surrounding tissues remain intact, with no evidence of thermal injury [13, 15, 16]. This difference may partially account for the reduced downtime and absence of crusting observed with P-DLA. Nevertheless, these interpretations remain speculative, as no histological validation was performed in the present study. Previous studies have demonstrated that picosecond lasers can effectively treat atrophic acne scars through photomechanical mechanisms across different wavelengths, devices, and skin types [17, 18, 22, 23]. In addition, several studies have further investigated the biological responses and potential mechanisms underlying picosecond laser-induced skin remodeling [13–15, 21]. However, comparative studies between picosecond lasers and NAFLs remain limited and have reported inconsistent findings. A study comparing P-DLA with a 1550-nm NAFL demonstrated superior improvement on the NAFL side, but fewer adverse effects on the P-DLA side [24]. In contrast, a study comparing a 1064-nm picosecond laser with a 1550-nm NAFL reported superior efficacy and fewer side effects on the picosecond laser side, whereas another reported no significant differences between the two modalities [20, 25]. Such variations may be related to differences in wavelength selection, treatment settings, and study protocols. Exploratory subgroup analyses showed no significant differences in treatment efficacy between P-DLA and NAFL across different scar subtypes. However, differences in scar morphology may influence treatment response, as scar types vary in depth and structural characteristics. Future studies with larger sample sizes should consider stratifying patients according to the predominant scar subtype to further investigate potential differences in treatment response. Overall, considering both prior studies and our findings, both P-DLA and NAFL are effective and safe modalities for the treatment of atrophic acne scars, with similar short-term efficacy. P-DLA may be more suitable for patients prioritizing minimal downtime and fewer adverse effects, whereas NAFL remains a valid and effective option given its established role in dermal remodeling. Consistent with our findings, previous studies have reported continued improvement in scar appearance during prolonged follow-up periods, suggesting that collagen remodeling and scar repair processes may continue after multiple treatment sessions [26, 27]. Longer follow-up periods are warranted in future studies and clinical evaluations to better characterize the long-term efficacy of these treatments. There are several limitations in this study. First, the sample size was relatively small, and the possibility of a Type II error cannot be excluded; thus, the absence of statistically significant differences does not establish equivalence in efficacy between P-DLA and NAFL. Second, the follow-up period was relatively short, limiting the assessment of long-term efficacy. Third, the efficacy assessment was based on semiquantitative clinical grading systems, which may be subject to interobserver variability. The use of objective tools, such as three-dimensional imaging or ultrasound, could provide more quantitative and reproducible evaluations of treatment efficacy. Fourth, the laser parameters were selected on the basis of previously published studies and clinical practice; however, differences in device characteristics and treatment protocols may introduce potential parameter selection bias. Additionally, multiple comparisons across outcome measures may increase the risk of Type I error, and the lack of an intention-to-treat analysis may introduce potential bias in the statistical analysis. Finally, all the enrolled patients were from a single ethnic background and had Fitzpatrick skin types III–IV, which may limit the generalizability of the findings. In conclusion, both P-DLA and NAFL were effective and safe for the treatment of atrophic acne scars, with similar efficacy between the two modalities. The P-DLA system was associated with a more favorable tolerability profile, characterized by reduced downtime and fewer adverse effects.